Release Date: June 30, 2025
Expiration Date: June 30, 2026
Activity Overview
Preliminary results from the recent CATALYST study found hypercortisolism in 24% of patients with type 2 diabetes who are screened for the condition. Given the high prevalence of hidden hypercortisolism among patients with type 2 diabetes, early identification and treatment of these patients may help improve outcomes.
This SimulatEd™ program is an online, on-demand activity designed to enhance clinical reasoning for health care providers involved in the diagnosis and management of hypercortisolism in patients with type 2 diabetes mellitus. It consists of a simulated patient encounter that requires learners to make clinical decisions and review updates from expert faculty on best practices in the diagnosis and management of hypercortisolism, fostering critical thinking and decision-making skills in a risk-free setting.
Target Audience
This educational activity is directed toward endocrinologists and diabetes specialists. Other HCPs involved in the care of patients with Cushing syndrome, such as NPs, PAs, RNs, will also find it useful.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Outline the role of hypercortisolism in the development of type 2 diabetes
- Describe risk factors for hypercortisolism in patients with type 2 diabetes
- Apply screening recommendations to identify hypercortisolism in patients with type 2 diabetes
- Analyze clinical trial data for therapies for hypercortisolism
Richard E. Pratley, MD
AdventHealth Samuel E. Crockett Chair in Diabetes Research
Medical Director, AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead, AdventHealth Translational Research Institute
Adjunct Professor of Medicine, Johns Hopkins University School of Medicine
Orlando, FL
Disclosures: Research / Grant Support; Biomea Fusion, Carmot Therapeutics, Dompe, Eli Lilly and Company, Endogenex Inc, Fractyl, Novo-Nordisk, Sanofi: Speaker’s Buearu; Lilly USA LLC, Novo-Nordisk: Consultant; AbbVie Inc, Altanine Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer AG, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Corcept Therapeutics Incorporated, Eli Lilly and Company, Endogenex Inc, F. Hoffmann-LA Roche Ltd, Gasherbrum Bio, Inc, Genprex, Getz Pharma, Hanmi Pharmaceutical Co, Intas Pharmaceuticals Inc, Lexicon Pharmaceuticals, Lilly USA LLC, Novo-Nordisk, Pfizer, Regneron, Scholar Rock Inc, Sun Pharmaceuticals Industries
Matthew P. Gilbert, DO, MPH
Professor of Medicine
Division of Endocrinology, Diabetes & Osteoporosis
Larner College of Medicine at The University of Vermont
Burlington, VT
Disclosures: Advisory Board; Novo Nordisk
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.